Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 22, 2019JAMA

Breast Cancer Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAdrienne G. WaksHarvard UniversityEWEric P. WinerYale Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Waks et al. (2019) studied this question.

synapsesocial.com/papers/693dfe7c35a649d042a9a123https://doi.org/10.1001/jama.2018.19323
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).2017 · 53 citations
  2. 2Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-272008 · 1,817 citations
  3. 3Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer2014 · 757 citations